Actively Recruiting
Evaluation of Inobrodib with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma in a Phase II Open-Label Study
Led by CellCentric Ltd. · Updated on 2026-09-21
100
Participants Needed
31
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the anti-cancer effects of inobrodib combined with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma MM that no longer responds to existing treatments. This Phase II, open-label, multicenter study focuses on patients who have previously been treated with specific therapies including proteasome inhibitors, anti-CD38 monoclonal antibodies, pomalidomide, and bispecific T-cell engagers. The goal is to better understand the treatments activity and side effects in this patient group. Participants will receive 20 mg of inobrodib orally twice daily for 4 days followed by 3 days off in each 28-day cycle. Pomalidomide will be given at 4 mg once daily on days 1 through 21 of each cycle, and dexamethasone at 40 mg on days 1, 8, 15, and 22. Treatment will continue until disease progression, unacceptable side effects, or other withdrawal criteria are met. Approximately 100 patients will receive this combination treatment. During the study, participants will undergo regular assessments to evaluate treatment response based on International Myeloma Working Group criteria, including objective response rate measured by an independent review committee. Additional outcomes include duration and time to response, survival rates, and monitoring of any adverse events. Assessments will continue until disease progression or up to 48 months from enrollment, with safety monitored 28 days after treatment ends.
CONDITIONS
Brief Title
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Research Team
C
CCS1477-04 Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here